219 related articles for article (PubMed ID: 29463038)
1. Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.
Ferreira MSV; Crysandt M; Braunschweig T; Jost E; Voss B; Bouillon AS; Knuechel R; Brümmendorf TH; Beier F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463038
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis.
Kunieda J; Yamashita K; Togashi Y; Baba S; Sakata S; Inamura K; Ae K; Matsumoto S; Machinami R; Kitagawa M; Takeuchi K
Cancer Sci; 2022 Mar; 113(3):1078-1089. PubMed ID: 34971481
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in soft tissue sarcomas.
Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
8. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
9. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
[TBL] [Abstract][Full Text] [Related]
10. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
[TBL] [Abstract][Full Text] [Related]
11.
Saito T; Akaike K; Kurisaki-Arakawa A; Toda-Ishii M; Mukaihara K; Suehara Y; Takagi T; Kaneko K; Yao T
Mol Clin Oncol; 2016 Jan; 4(1):61-64. PubMed ID: 26870359
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
[TBL] [Abstract][Full Text] [Related]
13. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
14. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutation in adult granulosa cell tumor of the ovary.
Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
[TBL] [Abstract][Full Text] [Related]
16. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
17. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
